Document Detail


Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients.
MedLine Citation:
PMID:  15205265     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An active assessment of the host capacity to prevent infection during myelosuppression should be beneficial in patients receiving high-dose chemotherapy. A single dose of granulocyte colony-stimulating factor (G-CSF) (5 microg/kg) was given to 57 patients with multiple myeloma early after the completion of 85 high-dose chemotherapy (melphalan 200 mg/m2) courses. This provoked a highly variable white blood cell (WBC) peak after 12 to 14 hours. The median WBC count was 21,000/microL (range, 6400-60,600/microL) after a first high-dose therapy (n = 50) and 13,500/microL (range, 4700-24,800/microL) after a second high-dose therapy (n = 35). The responsiveness to single G-CSF was associated with the risk of infection during subsequent cytopenia (P =.003). This association was significant after adjustment for neutropenia duration. Notably, the result of testing G-CSF responsiveness was opportunely available before the onset of leukopenia, and G-CSF responsiveness was more informative than neutropenia duration regarding the risk of infection. Furthermore, there was an association between the responsiveness to G-CSF and stem cell engraftment (P <.005), which remained significant after adjustment for the number of transplanted CD34+ cells. Our results show for the first time that G-CSF potentially could be used for an early in vivo assessment of defense to infection in recipients of high-dose chemotherapy.
Authors:
Christian Straka; Fuat Oduncu; Axel Hinke; Hermann Einsele; Evi Drexler; Brigitte Schnabel; Lubomir Arseniev; Jochem Walther; August König; Bertold Emmerich
Related Documents :
7919555 - Stability of ondansetron stored in polypropylene syringes.
8547065 - Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating facto...
1659535 - Granulocyte-macrophage colony stimulating factor does not improve neutrophil oxidative ...
7954995 - Optimal anti-emetic dose of granisetron for preventing postoperative nausea and vomiting.
3804125 - Bha study in pigs.
3412035 - Phase i trial of the combination of 6-methylmercaptopurine riboside and 5-fluorouracil.
Publication Detail:
Type:  Journal Article     Date:  2004-06-17
Journal Detail:
Title:  Blood     Volume:  104     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-09-20     Completed Date:  2004-11-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1989-94     Citation Subset:  AIM; IM    
Affiliation:
Medizinische Klinik-Innenstadt, Klinikum der Universität München, München, Germany. christian.straka@med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antigens, CD34 / chemistry
Antineoplastic Agents / adverse effects*
Blood Transfusion
Clinical Trials as Topic
Female
Granulocyte Colony-Stimulating Factor / therapeutic use*
Hematopoietic Stem Cells / cytology
Humans
Leukocyte Count
Leukocytes / cytology,  drug effects
Leukopenia / prevention & control*
Male
Middle Aged
Multiple Myeloma / drug therapy*
Neoplasms / drug therapy*
Prognosis
Risk
Stem Cells / cytology
Time Factors
Chemical
Reg. No./Substance:
0/Antigens, CD34; 0/Antineoplastic Agents; 143011-72-7/Granulocyte Colony-Stimulating Factor

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses.
Next Document:  Unusual immunophenotype of CD8+ T cells in familial hemophagocytic lymphohistiocytosis.